Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):446-9. doi: 10.1097/QAI.0b013e3182364513.

Abstract

Optimizing treatment for patients with persistent low-level viremia is complicated because most genotyping tests are validated for viral loads >1000 copies per milliliter. In this study, genotypes of 92 treatment-experienced patients with persistent low-level viremia were determined using an in-house assay. Based on the resistance profiles obtained from genotyping and patient pharmacologic history, patients were either maintained on their antiviral regimen (n = 51) or received an optimized regimen (n = 41). In the group receiving optimized treatment, undetectable viral loads were achieved in 73.2% at 6 months and at 90.2% at 1 year, indicating that treatment guided by genotyping of patients with low-level viremia is effective in achieving viral suppression.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Viral / genetics*
  • Female
  • Gene Expression Regulation, Viral
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Protease / genetics
  • HIV Protease / metabolism
  • HIV Reverse Transcriptase / genetics
  • HIV Reverse Transcriptase / metabolism
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Male
  • Middle Aged
  • Viral Load / drug effects
  • Viral Load / genetics
  • Viremia / blood*
  • Viremia / genetics

Substances

  • Anti-HIV Agents
  • HIV Reverse Transcriptase
  • HIV Protease